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DNA methylation is an epigenetic mechanism establishing long-term gene silencing during development
and cell commitment, which is maintained in subsequent cell generations. Aberrant DNA methylation is
found at gene promoters in most cancers and can lead to silencing of tumor suppressor genes. The DNA
methyltransferase inhibitor 5-aza-20-deoxycytidine (5-aza-CdR) is able to reactivate genes silenced by
DNA methylation and has been shown to be a very potent epigenetic drug in several hematological
malignancies. In this report, we demonstrate that 5-aza-CdR exhibits high antineoplastic activity against
anaplastic large cell lymphoma (ALCL), a rare CD30 positive non-Hodgkin lymphoma of T-cell origin. Low
dose treatment of ALCL cell lines and xenografted tumors causes apoptosis and cell cycle arrest in vitro
and in vivo. This is also reﬂected in genome-wide expression analyses, where genes related to apoptosis
and cell death are amongst the most affected targets of 5-aza-CdR. Furthermore, we observed deme-
thylation and re-expression of p16INK4A after drug administration and senescence associated b-galacto-
sidase activity. Thus, our data provide evidence that 5-aza-CdR is highly efﬁcient against ALCL and
warrants further clinical evaluation for future therapeutic use.
 2012 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
DNAmethylation is an epigenetic regulatory mechanism, which
occurs at cytosine residues mainly in CpG dinucleotides and
ensures long-term silencing of inactive genomic regions [1]. In
cancer, DNA methylation is decreased on a genome-wide scale, but
it is also directed to CpG islands, which are normally unmethylated
and may account for silencing of tumor suppressor genes [2].
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nder CC BY-NC-ND license.5-azacytidine (5-aza-CR, Vidaza) or the more stable 5-aza-20-
deoxycytidine (5-aza-CdR, decitabine, Dacogen) are used to
reverse DNA methylation in order to induce the re-expression of
silent genes [3,4]. Mechanistically, 5-aza-CR and 5-aza-CdR, which
are nucleoside analogs, work via incorporation into DNA of actively
proliferating cells. Upon incorporation, they irreversibly trap DNA
methyltransferases (DNMTs) by forming covalent complexes [5,6].
Thereby, they inhibit propagation of DNA methylation during each
round of replication at low doses, whereas at high doses cytotoxic
side effects can occur [7]. 5-Aza-CdR has been approved by the Food
and Drug Administration (FDA) for the treatment of myelodys-
plastic syndrome and low dose administration of 5-aza-CdR has
been tested in promising clinical trials of hematological malig-
nancies such as CML and AML, whereas less striking results have
been observed for solid tumors [8e11].
The systemic anaplastic large cell lymphoma (ALCL) is a rare
hematological malignancy of T-cell origin, with peak incidences in
children/young adults and in people over 60 years of age [12]. It is
classiﬁed as a CD30 positive non-Hodgkin lymphoma and can be
histopathologically characterized based on the appearance of large
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translocation (t(2; 5)(p23; q35)), which results in the generation of
the oncogenic fusion protein NPM-ALK (nucleophosmin-anaplastic
lymphoma kinase) [13e15]. The fusion protein acts as a constitutive
active kinase and aberrantly activates multiple cellular pathways
including JAK/STAT (Janus kinase/signal transducer and activator of
transcription), PI3-K/AKT (phosphatidylinositol-3 kinase/AKT),
MAPKs (mitogen-activated protein kinases), and PLCg (phospholi-
pase Cg), which lead to enhanced proliferation and cell trans-
formation [16e18].
DNA hypermethylation in ALCL was shown for a handful of
genes including the tumor suppressor p16INK4A and genes involved
in T-cell receptor signaling and T-cell identity [19e23]. Interest-
ingly, the inhibition of DNMT1 by DNMT1 antisense oligonucleo-
tides was capable to suppress activation of STAT3, providing
a molecular rationale to target DNA methylation by treatment with
epigenetic drugs in the disease [24].
Currently, the therapy for ALCL consists of standard chemo-
therapy, however, the efﬁciency of treatment schemes can be
limited due to the occurrence of relapses and development of drug
resistance when certain risk factors are present [25]. Thus, alter-
native therapy options need to be considered.
In the current study, we evaluated the in vitro and in vivo effects
of the DNMT inhibitor 5-aza-CdR on ALCL with a focus on ALK
positive (ALKþ) lymphoma cells. This study was prompted by the
ﬁnding that both ALKþ and ALK negative (ALK ALCL cells display
high expression levels of the main 5-aza-CdR) target DNMT1. Low
dose drug treatments resulted in increased apoptosis, cell cycle
arrest and a senescence-like phenotype as indicated by higher
b-galactosidase activity and demethylation and re-expression of
p16INK4A after drug administration. Global gene expression analysis
revealed cell death and apoptosis as central processes affected by
5-aza-CdR in KARPAS-299 cells, and our top de-regulated targets
included cancer testis antigens, genes involved in cell adhesion and
migration and in immune response. We conclude e based on our
in vitro and in vivo data e that 5-aza-CdR effectively blocks tumor
progression in ALCL and might represent a promising treatment
option for epigenetic therapy or combination with standard
chemotherapy in this disease entity.
2. Materials and methods
2.1. Human ALKþ and ALK ALCL patient samples
Archived formalin ﬁxed parafﬁn embedded (FFPE) tumors from
ALKþ and ALK ALCL patients and lymph node controls were ob-
tained blinded and randomized from the Institute of Clinical
Pathology at the Medical University of Vienna in accordance with
the declaration of Helsinki and Austrian legislature.
2.2. Immunohistochemistry
Tissue arrays containing 30 ALKþ samples, 5 ALK samples and
7 lymph nodes were dewaxed and rehydrated using standard
procedures. Epitopes were retrieved by heat-treatment in citrate
buffer (DAKO). Endogenous peroxidase was blocked with 3% H2O2
(GatteKoller) for 10 min. Sections were blocked with Avidin/Biotin
block (Vector) and Superblock (IDLabs). Slides were incubated with
primary antibody against DNMT1 (abcam, ab13537) or CD30
(DAKO, M0751) diluted in 1% PBS/BSA over night at 4 C, followed
by incubation with secondary antibody and Streptavidin HRP
(IDLabs). Arrays were stainedwith AEC (ID-Labs) for DNMT1 or DAB
(Thermo Scientiﬁc) for CD30 and counterstained with hematoxylin
(Merck). Pictures were taken with an Olympus Vanux AHBT3
microscope and the ProgRes C12 program.2.3. Cell culture
2.3.1. Cell lines and chemicals
KARPAS-299 and SR-786 (ALKþ ALCL) andMAC-2A (ALK ALCL)
human cell lines were grown in RPMI 1640 medium (GIBCO) con-
taining 10% FBS (fetal bovine serum) and 1% penicillin/streptomycin
at 37 C in an atmosphere of 5% CO2 and 95% room air. 5-Aza-20-
deoxycytidine (5-aza-CdR) was obtained from SigmaeAldrich,
dissolved in PBS (GIBCO) to a concentration of 1 mM and stored
at 80 C until use.
For population doubling analysis, MAC-2A, KARPAS-299 and SR-
786 cell lines were seeded in six-well plates (BD Biosciences) at
a density of 5105 cells/ml in RPMI medium. 5-Aza-CdR was added
either once (d0) or every other day (d0, d2, d4) to a ﬁnal concen-
tration of 1 mM and PBS was added to control cells. After 2, 4 and 6
days cells were counted using a CASY cell counter (Schaerfe
System), centrifuged and diluted to 5105 cells/ml in fresh RPMI
medium. Population doublings between measurements were
calculated according to the formula: population doublings ¼ ln
(concentration counted/concentration seeded) and overall pop-
ulation doublings were calculated by summing up preceding
values.
2.3.2. Cell cycle analysis
For cell cycle analysis, KARPAS-299 cells were incubated for 24 h
with 1 mMof 5-aza-CdR in RPMI and grown for 4 days in fresh RPMI
only. Then, 105e106 cells were suspended in 500 ml PI-buffer (0.1%
Naecitrat dihydrate (Sigma), 0.1% Triton X-100 (Sigma), 0.1% RNAse
(DNAse free, Sigma) in PBS). Propidiumeiodide (ROTH, dissolved in
PBS) was added to a concentration of 10 mg/ml and the cells were
incubated for 30 min at 37 C. The analysis was performed on a BD
FACSCanto II ﬂow cytometer using the BD FACS Diva Software.
Three independent samples of 5-aza-CdR treated and PBS controls
were analysed. Descriptive statistics for analysis are reported as
mean  SEM.
2.3.3. Methylation analysis by Combined Bisulﬁte Restriction
Analysis (COBRA)
For methylation analysis, 1 106 KARPAS-299 and MAC-2A cells
were incubated with 0, 1 and 10 mM of 5-aza-CdR in RPMI, the
medium was changed after 24 h and then cells were grown for 4
days in RPMI only. Cells were centrifuged, washed and dissolved in
genomic DNA isolation buffer (0.4 M NaCl, 0.2% SDS, 0.1 M Tris pH
8.3, 5 mM EDTA). After RNAse A (20 mg/ml, Invitrogen) and
Proteinase K (500 mg/ml, Invitrogen) digestion at 55 C over night,
phenol/chloroform extraction was performed and the DNA was
precipitated with 1vol. of isopropanol. The DNA pellet was
washed with 75% ethanol, dried at room temperature, dissolved in
sterile water and incubated at 37 C until completely dissolved.
DNA concentration was measured on a Nanodrop 2000 (Thermo
Scientiﬁc). To obtain a methylated control, 20 mg of DNA isolated
from PBMCsweremethylated byM.SssI (NEB, 80U) in vitro for 6 h at
37 C with 160 mM S-adenosylmethionine (NEB) and puriﬁed by
phenol/chloroform extraction as described above.1 mg of DNA was
bisulﬁte-converted with the EZ DNA Methylation Kit (Zymo
Research) according to the manufacturer’s protocol. Over night
conversionwas carried out in a thermocycler at 95 C for 30 s, 50 C
for 60 min (16 cycles). For COBRA-PCR, a PCR reaction contained
2.5 ml 10 AmpliTaqGold Buffer (Applied Biosynthesis), 2.5 ml
MgCl2 (Applied Biosynthesis), 0.5 ml dNTPs (Invitrogen), 1 ml 10 mM
p16INK4A primers (forward þ reverse), 0.125 ml AmpliTaqGold
Polymerase (Applied Biosynthesis), 16.5 ml H2O and 2 ml of bisulﬁte-
converted DNA. Primers for ampliﬁcation of bisulﬁte converted
DNA were designed using the SEQUENOM EpiDesigner program
(http://www.epidesigner.com/). Primer sequences used were
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ATC CCT CAA ATC CTC TAA AAA-30 (PCR product size: 220 bp,
restriction by TaqI: restriction fragments 150 bp and 70 bp).
Restriction of the PCR product for the p16INK4A promoter was per-
formed for 3 h at 65 C by incubation with TaqI (New England Bio
Labs) (15 ml PCR product, 2 ml 10 NEB buffer 4, 2 ml 10 BSA, 0.5 ml
TaqI, 0.5 ml H2O). Restriction fragments were analyzed on an Agilent
2100 Bioanalyzer platform using the Agilent DNA chip 1000 series.
Chip preparation was carried out according to the manufacturer’s
protocol. 1 ml of the restriction product was loaded onto the chip.
For quantiﬁcation of methylated and unmethylated fragments, the
areas under the methylated and unmethylated peaks in electro-
pherograms were measured by Agilent software and the
percentage of methylated or unmethylated fragments in relation to
total peak areas was calculated.
2.3.4. RNA extraction, gene expression proﬁling and quantitative
reverse transcription PCR (qRTePCR)
For gene expression analysis, 1  106 KARPAS-299 cells were
incubated with 1 mM of 5-aza-CdR or PBS for 24 h in RPMI, the
medium was changed to RPMI only and the cells were grown for 4
days. Then, cells were centrifuged, washed and RNA was extracted
using the RNAeasy Mini kit (Qiagen) according to protocol. RNA
concentration was measured on the Nanodrop 2000 (Thermo
Scientiﬁc) and RNA quality was determined on an Agilent 2100
Bioanalyzer platform. Total RNA (200 ng) was then used for
GeneChip analysis. Preparation of terminal-labeled cDNA, hybrid-
ization to genome-wide human Gene Level 1.0 ST GeneChips
(Affymetrix, Santa Clara, CA, USA) and scanning of the arrays were
carried out according to manufacturer’s protocols https://www.
affymetrix.com.
For qRTePCR quantiﬁcation, 1 mg of RNA was used as template
for random hexamer cDNA synthesis (Invitrogen) using Superscript
(200 U/ml) (Invitrogen) according to supplier’s protocol. qRTePCR
was performed with FASTAKapa Mastermix (Peqlab biotechnol-
ogies) on a Biorad cycler, 2 ml of cDNA were used per sample.
GAPDH was used for normalisation. RT-primer sequences for
p16INK4A were fw: 50-GGG TCG GGT AGA GGA GGT G-30 and and rv:
50-ACG GGT CGG GTG AGA GTG-30 and for GAPDH fw: 50-GGT GGT
CTC CTC TGA CTT CAA CA-30 and rv: 50-GTT GCT GTA GCC AAA TTC
GTT GT-30. Three independent samples were processed. RT-primer
sequences for conﬁrmation of array datawere: MAGE2B fw: 50-CAG
GGG TGA ATT CTC AGG AC-30, rv: 50-GGC CTC TTC TTC CTC TGC TT-
30, MMP13 fw: 50-GGT TCC TGA TGT GGG TGA AT-30, rv: 50-CAA TGC
CAT CGT GAA GTC TG-30, SPARC fw: 50-CAG AAC CAC CAC TGC AAA
CA-30, rv: 50-AAG TGG CAG GAA GAG TCG AA-30, TGFB1 fw: 50-GAG
CCT GAG GCC GAC TAC TA-30, rv: 50-GGG TTC AGG TAC CGC TTC TC-
30, TNFAIP2 fw: 50-CTG GAC TTG GGC TCACAGAT-30, rv: 50-CAG GCA
GTT GTT GAT GTT GG-30and CXC11 fw: 50-GCA GCA AAG CTG
AAGTAGCA-30, rv: 50-ATG CAA AGA CAG CGT CCT CT-30.
2.3.5. Bioinformatic analysis of global gene expression
Statistical analyses were conducted with the bioconductor
packages Affy and limma [26e28]. Quality assessment was done by
boxplots, histograms and correlation plots. We normalized the data
using the robust multi-array average (RMA) expression measure.
Before starting the analyses, we ﬁltered the data. Probes were
included in the analysis if the IQR over all chips was greater than 0.5
and if at least two of the chips showed intensity above the cut point
of log 2 (100). After ﬁltering the data, 4901 of 32,321 probes
remained. For comparison of the chips we calculated moderated t-
statistics (bioconductor package limma) and corrected for multiple
testing by BenjaminieHochberg correction. The analysis was
repeated without ﬁltering the data and including only genes that
are described in Gius [29] and Carén [30], respectively. In total, 943genes were selected for the statistical analysis. Thereof, 725 probes
could be assigned to a gene symbol. For pathway analysis, we used
ingenuity pathway analysis (IPA) software (http://www.ingenuity.
com/). For all analyses, the signiﬁcance level has been set to 0.05.
2.3.6. Doseeresponse curve
For doseeresponse curves, 5  10 ˇ5 cells/ml were incubated
with 0.01, 0.03, 0.1, 0.3,1, 3 and 10 mMof 5-aza-CdR for 24 h in RPMI,
the medium was changed and cells were grown for 4 days. Then,
5  104 cells of each concentration were plated in 96 well dishes in
triplicates, 0.1 mCi [3H]ethymidine/well (PerkineElmer) were
added and cells were incubated for another 12 h. After 12 h of
incubation, [3H]-incorporationwas measured with Ultima Gold MV
scintillation ﬂuid (Packard Instruments) by a scintillation counter.
The doseeresponse curve (log c vs counts per minute/CPM) was
calculated by assuming a sigmoid doseeresponse curve (variable
slope).
2.3.7. Protein extraction and Western Blot
Human peripheral blood mononuclear cells (PBMCs) were iso-
lated from 50 ml of whole blood obtained from a healthy female
volunteer using Lymphoprep solution (Axis-shield) according to
manufacturer’s protocol.
PBMC, MAC-2A, KARPAS-299 and SR-786 cell pellets were dis-
solved in Hunt buffer (20 mM Tris pH 8, 100 mM NaCl, 1 mM EDTA,
0.5% NP-40, protease inhibitor (Roche)), frozen in liquid nitrogen,
put at 37 C to thaw, then frozen again and put on ice until
completely thawed. The solutionwas centrifuged for 10 min at 4 C
and protein concentration of the supernatant was measured using
the Nanodrop 2000 (Thermo Scientiﬁc). Samples were diluted with
2 protein loading dye (100 mM TriseHCl pH 6.8, 200 mM DTT, 4%
SDS, 20% Glycerin, bromophenolblue), heated for 5min at 95 C and
loaded onto SDSePAGE (5e15%) gradient gels. 50 mg of proteinwere
loaded per lane. The gels were transferred onto nitrocellulose
membranes (wet o/n transfer at 25V, Biorad). Membranes were
blocked in blocking solution (5% milk powder, 0.02% NaN3) (Sigma)
in TBS-T (TBS containing 1% Triton-X100, Sigma) for 1 h at RT and
incubated with primary antibody against DNMT1 (abcam,
ab13537), ALK1 (Zymed, 51-3900) or CD30 (DAKO, M0751) (all
1:1000 in blocking solution), o/n at 4 C. After washing, incubation
with secondary antibody (1:10,000) for 1 h at RT and againwashing
with TBS-T, the membranes were incubated with chemo-
luminiscent solution ECL plus (GE Healthcare) and signals were
detected using the Lumi Analyst (Roche Applied Science). The same
membranes were incubated with b-Actin antibody (Cell signaling,
#4967) (1:1000 in blocking solution) as loading control as
described above.
2.3.8. b-Galactosidase staining
KARPAS-299 cells were incubated for 24 h with 1 mM of 5-aza-
CdR in RPMI and grown for 4 days in fresh RPMI only. Then,104e105
cells were centrifuged onto glass slides, washed in PBS and ﬁxed
and stained for b-galactosidase with the senescence b-galactosi-
dase staining kit (cell signaling, #9860) according to protocol.






Laboratories) mice were used in collaboration with the Pharma-
cology Department of the Medical University of Vienna. All animal
experiments were carried out in accordance with the Austrian Act
on Animal Experimentation 1988 (GZ 66.009/139-II/10b/2009). The
mice were kept in a controlled environment of light, humidity and
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299 human cells were grown as described above, dissolved in
sterile PBS to a concentration of 1107 cells/ml and inoculated
subcutaneously (1106 cells/injection) into the right and left ﬂanks
of the mice. Tumor range was followed measuring tumor length
and tumor width with a calliper.
2.4.2. Treatment procedure
Mice weighed approximately 25 g at the beginning of the
therapy. 5-Aza-CdR was dissolved in sterile PBS and was adminis-
tered intraperitoneally (i.p.). Each mouse received 2.5 mg/kg/
mouse per treatment. Control mice were administered 100 ml of
sterile PBS. Therapies were adjusted regarding start and duration of
the treatment in order to obtain optimal treatment procedures. In
schedule A (Supplementary Fig. S2A), three mice were treated with
5-aza-CdR 11 days after inoculation, when tumor size was
approximately 1 cm2. The control group contained two mice. The
mice received 5-aza-CdR or PBS every day for eight days. In the
schedule B, two mice were treated with 5-aza-CdR three days after
inoculation and three mice ﬁve days after inoculationwhen tumors
were not or just palpable. 5-Aza-CdR was administered every other
day for ﬁve times to each mouse. The control group contained two
mice.
2.4.3. Cell cycle analysis
For cell cycle analysis, 100 mg of freshly isolated tumor tissue
were pressed through a 100 mm cell strainer (BD Biosciences) and
the cell suspension was propidiumeiodide stained and further
processed as described above for cell lines. Descriptive statistics for
analysis are reported as mean  SEM.
2.4.4. Immunohistochemistry
Tumor tissue was cross-linked in 4% paraformaldehyde, dehy-
drated in ethanol and embedded in parafﬁn. 3 mM sections were
cut, attached to slides, dewaxed and rehydrated. Epitopes were
retrieved by heat-treatment in citrate buffer (DAKO) and slides
were processed as described above for tissue arrays. Sections wereFig. 1. Enhanced DNMT1 expression is detected in human ALCL cell lines and patient sample
blood mononuclear cells (PBMCs). Proteins were extracted from PBMCs, ALK ALCL cell line
Blot as described in materials and methods. B. DNMT1 is expressed in human ALKþ ALCL
DNMT1 was performed on a human ALCL tissue array containing 30 ALKþ and 5 ALK ALCL p
one representative ALKþ and one ALK ALCL sample are shown. CD30 is used as diagnostic
positive cells compared to healthy lymphocytes.incubated with primary antibody against Ki-67 (Novocastra, NCL-
KI67-P) or Caspase3 (Cell signaling, #9661) diluted in 1% PBS/BSA
over night at 4 C. Slides were stained with AEC (ID-Labs) and
counterstained with hematoxylin (Merck). Hematoxilin and eosin
staining was done using an automatic tissue stainer (Medite).
2.4.5. Protein extraction and Western Blot
For protein extraction from tumors, tumor tissue was dounced
10e15 times in lysis buffer (20 mM Tris pH 8, 100 mM NaCl, 1 mM
EDTA, 0.5% NP-40, protease inhibitor (Roche)). The homogenate
was frozen in liquid nitrogen, put on ice to thaw and centrifuged at
4 C. Protein concentration in the supernatant was measured on
a Nanodrop 2000 (Thermo Scientiﬁc). SDSePAGE and Western Blot
were carried out as described above for cell lines.
2.4.6. Statistics
Results are shown as means  SEM. The signiﬁcance of the
differences between mean values was determined by one-way
ANOVA followed by pair wise comparisons to the control group
using unpaired t-tests.
3. Results
3.1. High expression levels of DNMT1 in human ALCL cell lines and
primary tumors
DNMT1 is essential for development and the proliferation of
cancer cells [31e33]. As DNMTs might represent a therapeutic
window for epigenetic therapy, we were interested to investigate
DNMT1 expression in ALCL cells. Western Blot analysis revealed
high DNMT1 levels in ALKþ cell lines KARPAS-299 and SR-786 as
well as in the ALK cell lineMAC-2A. In contrast, we failed to detect
DNMT1 expression in normal peripheral blood mononuclear cells
(PBMCs) isolated from a healthy donor (Fig. 1A). The ﬁndings
prompted us to further investigate DNMT1 expression in human
patient samples. A tissue array consisting of 30 formalin ﬁxed
parafﬁn embedded (FFPE) tumors from ALKþ ALCL patients, 5s. A. DNMT1 is overexpressed in human ALCL cell lines compared to normal peripheral
MAC-2A and ALKþ ALCL cell lines KARPAS-299 and SR-786 and analysed by Western
tumor cells, but not in healthy lymph nodes. Immunohistochemical staining against
atient samples and 7 normal lymph nodes as controls. One representative lymph node,
marker for ALCL. Note the typical abnormal anaplastic large cell morphology of CD30
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individuals as controls was manufactured and stained for DNMT1
expression. High DNMT1 expression was found in all CD30 positive
ALCL cells, whereas only minor DNMT1 expression was detected in
control lymph nodes (Fig. 1B).
3.2. 5-Aza-20-deoxycytidine inhibits proliferation of ALCL cells
5-Aza-20-deoxycytidine (5-aza-CdR) is a potent DNMT inhibitor
and has recently been approved by the FDA [4]. The high levels of
DNMT1 expression detected in ALCL prompted us to study the
effects of this drug and to test whether these cells are particularly
sensitive to inhibition of DNA methylation. Thus, we incubated
ALKþ KARPAS-299 and SR-786 and ALK MAC-2A cells with 1 mM
5-aza-CdR for six days, counted cells and calculated overall pop-
ulation doublings for this period. 5-Aza-CdR was added either once
at the beginning of the treatment (d0) or every second day (d0, d2,
d4) when the growth medium was changed. After four days in
culture, a clear decrease in population doublings could be observed
for all three cell lines upon treatment with 5-aza-CdR, irrespective
whether the drug had been applied once or multiple times (Fig. 2A
and Supplementary Fig. S1). Cell cycle analysis of KARPAS-299 cells
after 4 days showed an increase of 5-aza-CdR treated cells in G1
phase compared to PBS treated control cells (70.4%  0.7% vs
63.8%  1.9%) and a decrease of 5-aza-CdR treated cells in S phaseFig. 2. 5-Aza-CdR inhibits ALCL cell proliferation in vitro. A. Treatment of ALCL cell lines with
aza-CdR was either administered once (d0) or every other day (d0, d2, d4) to the ALKþ AL
doublings were calculated as described in materials and methods. Values are means  SD.
KARPAS-299 cells compared to control cells shows an increase in G1, a decrease in S and an
PBS for 4 day as described in A. Percentages are means  SEM. The analysis was performed
curve for KARPAS-299 cells treated with different 5-aza-CdR concentrations. The EC50 value
with 0.01, 0.03, 0.1, 0.3, 1, 3 and 10 mM of 5-aza-CdR for 24 h, the medium was changed and c
96 well dishes in triplicates and incubated with 0.1 mCi [3H]ethymidine/well for 12 h [3H
doseeresponse curve (variable slope) was assumed. Log concentration was plotted versus c(25.9%  0.6% vs 34.7%  1.9%). In addition, the viability of the cells
was impaired, and 5-aza-CdR treated cells showed a signiﬁcant
increase of apoptotic cells when compared to mock treated
cells (33.7%  0.8% in 5-aza-CdR treated versus 23.0%  1.4% in
control cells) (Fig. 2B). The EC50 value was determined by
measuring [3H]ethymidine uptake in KARPAS-299 cells after
incubation with increasing 5-aza-CdR concentrations. It was
calculated by analysing the resulting doseeresponse curve (Fig. 2C).
The EC50 value was 0.49 mM, which is in a similar range to the ones
observed in common AML cell lines [34].
3.3. 5-Aza-CdR induces demethylation and re-expression of the
tumor suppressor p16INK4A
5-Aza-CdR inhibits propagation of DNA methylation and
induces re-expression of methylated genes [35,36]. Some of these
methylated genes play a crucial role in controlling cell cycle
progression, i.e tumor suppressor p16INK4A (cyclin-dependent
kinase inhibitor 2A CDKN2A). p16INK4, which is controlling cell
cycle progression through the G1 phase, is capable to induce
senescence and has been reported to be methylated in some ALCL
tumor cells [19]. When we analysed the p16INK4A promoter meth-
ylation status by COBRA, we found that the promoter of p16INK4A
was methylated in KARPAS-299 cells and methylation decreased
upon 5-aza-CdR treatment in a dose dependent manner (Fig. 3A).5-aza-CdR leads to a decrease in population doublings after 4 days in culture. 1 mM of 5-
CL cell line KARPAS-299. Cells were counted using a CASY cell counter and population
Each value is the mean of three replicates. B. Cell cycle analysis of 5-aza-CdR treated
increase in apoptotic cells. KARPAS-299 cells were treated with 1 mM 5-aza-CdR (d0) or
with three replicates. Two representative FACS graphs are shown. C. Doseeresponse
for 5-aza-CdR treated KARPAS-299 cells is 0.49 mM. 5  10^5 cells/ml were incubated
ells were grown for four days. Then, 5  10^5 cells of each concentration were plated in
]-incorporation was measured by liquid scintillation counting. For analysis, a sigmoid
ounts per minute (CPM).
Fig. 3. 5-Aza-CdR treatment leads to demethylation and re-expression of the tumor suppressor p16INK4A and induces cellular senescence. A. p16INK4A promoter methylation
decreases upon treatment with increasing 5-aza-CdR concentrations. 1  106 KARPAS-299 cells were incubated with 0, 1 and 10 mM of 5-aza-CdR, the medium was changed after
24 h and then cells were grown for 4 days. DNAwas extracted from cells and bisulﬁte converted and Combined Bisulﬁte Restriction Analysis (COBRA) was performed to analyse the
methylation status of the p16INK4A promoter as described in materials and methods. Restriction fragments were analysed using the Agilent 2100 Bioanalyzer platform. Note the
dose-dependent increase of the unmethylated fragment at 220 bp indicated by the arrow. B. p16INK4A mRNA increases in the 5-aza-CdR treated cell line KARPAS-299 compared to
mock treated controls. RNA was isolated from 1 mM 5-aza-CdR treated KARPAS-299 cells as described in A. p16INK4A expression was analysed by quantitative RTePCR. Values are
means  SEM. Each value is the mean of three replicates. Data were analysed by unpaired t-tests. C. Senescent cells accumulate upon 5-aza-CdR treatment. 5-Aza-CdR treated
KARPAS-299 and control cells were stained for b-galactosidase activity and counterstained with nuclear fast red. Note the abnormal enlarged shape of 5-aza-CdR treated cells.
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pronounced due to lower p16INK4A promoter methylation levels
(Supplementary Fig. S2A). Quantitative RTePCR showed induction
of p16INK4A expression after 5-aza-CdR administration in KARPAS-
299 cells and to a lower level in MAC-2A cells (Fig. 3B and
Supplementary Fig. S2B). Re-expression of p16INK4A prompted us to
investigate whether 5-aza-CdR treatment could induce senescence
in KARPAS-299 cells, as p16INK4A is a key regulator of the Rb
pathway and cellular senescence [37]. Indeed, 5-aza-CdR treated
KARPAS-299 cells displayed a high percentage of senescent cells, as
indicated by b-galactosidase staining, compared to untreated
controls (Fig. 3C). Thus, 5-aza-CdR exerts pleiotropic effects on
KARPAS-299 cells including apoptosis, cell cycle arrest and
increased senescence associated b-galactosidase activity in vitro.
3.4. Global gene expression analysis of 5-aza-CdR treated ALKþ
ALCL cells
In order to study the effects of inhibition of DNMTs and DNA
methylation in ALKþ ALCL on global gene expression, we treated
KARPAS-299 cells with 1 mM 5-aza-CdR and performed gene
expression analysis using Affymetrix gene level arrays. After quality
control, normalization and ﬁltering, we identiﬁed 492 genes to be
differentially expressed (unadjusted p-value < 0.05) after 5-aza-CdR treatment. Our 31 top differentially expressed genes after
taking a cut-off of an adjusted p-value < 0.2 included nine cancer
testis antigens, such as DAZ1, DAZL, CT45A6, and MAGE2B, which
are normally not expressed in adult tissue except for testis, but are
known to be activated upon DNMT inhibitor treatment [38]. Eight
of the 31 genes are involved in cell migration and adhesion, ﬁve
genes are associated with immune responses and four genes with
cell migration and adhesion and immune responses (Fig. 4A and
Supplementary Table 1). We independently conﬁrmed increased
expression of MAGE2B, MMP13, SPARC, TGFB1, TNFAIP2 and
CXCL11 by qRTePCR after 5-aza-CdR treatment (Fig. 4B).
Pathway analysis of all 492 genes (unadjusted p-value< 0.05) by
using ingenuity pathway analysis (IPA) software revealed cancer as
top associated “biological function”. Further changes were detected
for genes involved in cellular movement, inﬂammatory response,
cell death and cellular growth and proliferation (Fig. 4C). Interest-
ingly, the most affected transcription regulators included p53,
which is in accordance with our observation that 5-aza-CdR leads
to apoptosis and re-expression of epigenetically silenced tumor
suppressors, and STAT3, which is an important down-stream
mediator of ALKinduced signaling (Supplementary Table 2). We
repeated the analysis with preselected genes including only genes
that have been previously deﬁned in response to 5-aza-CdR treat-
ment to further validate our data [29,30]. Of these 725 preselected
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p-value < 0.05) in KARPAS-299 cells after 5-aza-CdR treatment.
After correction for multiple testing, eight genes remained signiﬁ-
cant (adjusted p < 0.05). Seven of these were found in our top 31
differentially regulated genes (Supplementary Table 3). In
summary, our analysis detected deregulation of previous targets of
5-aza-CdR involved in apoptotic pathways, cellular growth and
proliferation.
3.5. 5-Aza-CdR inhibits tumor growth of ALKþ cells in a murine
xenograft model
To test the effects of 5-aza-CdR treatment on tumor growth and
proliferation in vivo, we performed murine xenograft experiments
employing different drug schedules. 1  106 ALKþ KARPAS-299
cells were subcutaneously injected into both ﬂanks of SCID mice.
In initial experiments, mice were treated with 2.5 mg/kg/mouse of
5-aza-CdR by intraperitoneal injection every day (treatment
schedule Supplementary Fig. S3A). The time point of 5-aza-CdR
administration after tumor injection signiﬁcantly affected tumor
growth. If 5-aza-CdR was administered for the ﬁrst time 11 days
after tumor inoculation, when tumor size already exceeded 1 cm2,
and then for a period of eight days, a slight but not statistically
signiﬁcant decrease in tumor weight was detected compared to
control mice (Supplementary Fig. S3B). To optimize treatment
outcome, we initiated treatment at an earlier stage and reduced theFig. 4. Gene expression analysis of 5-aza-CdR treated KARPAS-299 cells. A. Heat map showi
normalization, ﬁltering and statistical analysis of array data was performed as described in
antigens, genes involved in cell adhesion and migration, and genes associated with immune r
SPARC, TGFB1, TNFAIP2 and CXCL11) conﬁrms up-regulation after 5-aza-CdR treatment. C. P
cell death and cellular growth and differentiation as top “biological functions” affected bytotal amount of drug given. The animals were treated with 5-aza-
CdR three days (two mice) or ﬁve days (three mice) after injection;
thereafter treatment was continued every other day. Thereby, each
mouse received ﬁve dosages of 5-aza-CdR in total. The control
group contained two mice. As depicted in Fig. 5A, tumors from
5-aza-CdR treated mice were much smaller and tumor weight was
signiﬁcantly reduced in both treatment groups compared to the
control group (Fig. 5B). Immunohistochemical staining for tumor
proliferation by Ki-67-antibody revealed reduced Ki-67 expression
in 5-aza-CdR treated tumors. Histology staining of 5-aza-CdR
tumors showed large necrotic areas and increased apoptosis was
detected by staining for caspase3 in FFPE sections of treated tumors
(Fig. 5C).
FACS analysis revealed that 58% 5.1% and 44.9% 7.0% of tumor
cells from 5-aza-CdR day 3 and 5-aza-CdR day 5 groups, respec-
tively, were apoptotic, versus 29.5%  3.2% in controls (Fig. 6A).
DNMT1 protein was not detectable in protein extracts derived from
5-aza-CdR treated tumors as compared to controls, indicating a very
efﬁcient inhibition of DNMT1 by 5-aza-CdR incorporation into the
tumor DNA (Fig. 6B). In accordance with these ﬁndings, all 5-aza-
CdR treated tumors displayed demethylation at the p16INK4A
promoter, which ranged from fully methylated in untreated to
about 50% methylated in treated tumors, respectively (Fig. 6C and
D). Therefore, we conclude that 5-aza-CdR shows high efﬁcacy on
ALCL xenografts in vivo and causes increased apoptosis and reduced
proliferation of engrafted tumors.ng the top 31 differentially regulated genes after 5-aza-CdR treatment. Quality control,
materials and methods. The top 31 differentially expressed genes include cancer testis
esponse. B. qRTePCR validation of six differentially expressed genes (MAGE2B, MMP13,
athway analysis by IPA identiﬁes cancer, cellular movement, inﬂammatory responses,
5-aza-CdR.
Fig. 5. 5-Aza-CdR inhibits ALCL cell proliferation in murine xenografts. A. 5-Aza-CdR treated mice develop no or smaller tumors compared to PBS treated controls. 1  106 ALKþ
KARPAS-299 cells were subcutaneously injected into both ﬂanks of SCID mice. Mice were treated with 2.5 mg/kg/mouse of 5-aza-CdR by intraperitoneal injection three days (two
mice) or ﬁve days (three mice) after injection, respectively. Treatment was continued every other day and each mouse received ﬁve 5-aza-CdR treatments in total. The control group
contained two mice. Representative 5-aza-CdR and control tumors are shown. B. Tumor weight of 5-aza-CdR samples is signiﬁcantly decreased compared to controls. The aligned
dot blots show means  SEM. Tumor weights were analysed by one-way ANOVA (p < 0.05) followed by pair wise comparisons to the control group using unpaired t-tests. C.
Immunohistochemical analysis of 5-aza-CdR tumors shows increased necrotic areas in hematoxylin and eosin (HE), decreased proliferation by Ki-67 staining and increased
apoptosis by Caspase3 staining compared to PBS controls. Representative tumors of both treatment schedules and controls are shown.
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The DNMT inhibitor 5-aza-CdR is approved for the treatment of
myelodysplastic syndrome and is tested in clinical trials for AML
and CML, making it a promising therapeutic possibility for hema-
tological malignancies [8,9,39,40]. In the current study, we
observed a strong antineoplastic activity of 5-aza-CdR on anaplastic
large cell lymphoma, a rare and aggressive CD30 positive
lymphoma of T-cell origin [12]. ALCL cells displayed high DNMT1
expression, which is considered a sign for actively proliferating
cells and a prerequisite for 5-aza-CdR incorporation into DNA. ALCL
cells responded to drug treatment with signiﬁcantly decreased cell
proliferation, G1 arrest, increased apoptosis and loss of methyla-
tion. These effects were visible only after several days in culture, as
would be expected for a mechanism involving passive DNA
demethylation and no cytotoxicity. Notably, we observed an EC50
value of 5-aza-CdR for the ALKþ Karpas-299 cell line in the same
range as those reported for four common AML cell lines (0.49 mMvs. 0.4e0.8 mM) [34]. 5-Aza-CdR plasma concentrations measured
in clinical studies vary between 0.3 and 1.6 mM, indicating that
5-aza-CdR concentrations determined in vitro for successful ALCL
proliferation inhibition could potentially be achieved in humans
[41,42]. Our xenograft studies showed that the effects obtained
in vitro can also be observed in vivo regarding tumor growth
inhibition, induction of apoptosis, and demethylation of candidate
genes. Early administration time points were critical for effective
drug action, probably due to the high aggressivity of the tumors. In
addition, possible inhibitory effects of 5-aza-CdR on blood vessel
formation have been observed in different tumor models, which
might in part be responsible for the pronounced effect on tumor
cell growth in our xenograft model [43].
Global gene expression analysis revealed that main changes
induced by 5-aza-CdR concerned genes related to cell death, which
is in line with our ﬁnding that 5-aza-CdR leads to reduced cell
proliferation and apoptosis. Changes were also observed for genes
involved in cell adhesion and migration and in immune response.
Fig. 6. 5-Aza-CdR treatment in vivo leads to inhibition of DNMT1 and apoptosis and results in demethylation of tumor suppressor p16INK4A. A. Cell cycle analysis shows that 5-aza-
CdR treatment leads to increased apoptosis. Tumor samples were prepared for FACS analysis as described in the methods section and analyzed with a BD FACSCanto II ﬂow
cytometer using the BD FACS Diva Software. Values are means  SEM. Each value is the mean of three replicates for control and 5-aza-CdR day 5 tumors and of two replicates for 5-
aza-CdR day 3 tumors. B. DNMT1 is not detected in tumor protein extracts derived from 5-aza-CdR treated mice. Proteins were extracted from tumor tissue from two tumors treated
with 5-aza-CdR starting on day 3 and three tumors treated with 5-aza-CdR on day 5 as described in materials and methods. DNMT1 protein levels were analysed byWestern Blot. C.
Analysis of the p16INK4A promotor region by COBRA shows demethylation after 5-aza-CdR treatment. DNA was extracted from tumor tissue, bisulﬁte converted and analysed by
COBRA. Restriction fragments were analysed using the Agilent 2100 Bioanalyzer platform. Normal PBMCs and in vitro by M.SssI methylated PBMCs were used as unmethylated and
methylated controls, respectively. Note the re-appearance of the unmethylated fragment in treated samples indicated by the arrow. D. The percentage of methylated fragments is
signiﬁcantly reduced in 5-aza-CdR treated tumors. Percentages of methylated and unmethylated fragments in relation to total peak areas in electropherograms were calculated with
Agilent software as described in the methods section.
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for proliferation and differentiation of immune cells, was reported
to be a marker for malignant transformation and drug sensitivity in
melanoma cells [44]. Interestingly, its expression was observed to
be low in ALKþ Karpas-299 compared to other ALKþ cell lines [45].
We also detected up-regulation of several cancer testis antigens
such asMAGEB2, CT45A6, DAZL and BORIS/CTCFL, a ﬁnding that has
regularly been reported for studies on DNA demethylation after
5-aza-CdR treatment [38,46]. Up-regulation of cancer testis anti-
gens by DNA methylation inhibitors might represent a way to
generate novel targets for cancer immunotherapy, as cancer testis
antigens are not expressed in normal adult tissues except for testis
or placenta [47].
Concerning the mechanism of action of 5-aza-CdR on tumor
cells, the general hypothesis is that reversal of epigenetic gene
silencing of tumor suppressors can contribute signiﬁcantly to the
proliferation inhibiting effects of the drug [4,48]. In our study, we
observed demethylation and re-expression of the tumor suppressor
p16INK4A (CDKN2A), which is involved in cell cycle G1 control by
inhibiting cyclin-dependent kinase 4 (CDK4) and is epigenetically
silenced in ALCL [19]. It has recently been shown that activation of
the p16INK4A/pRB pathway represents an alternative route to
oncogene-induced senescence in ALKþ ALCL [37]. The presence of
p16INK4A expressing cells was described in premalignant lesions of
NPM-ALK transgenic mice rendering these cells senescent, whereasin the absence of p16INK4A tumors evolve rapidly. In line with this
and our ﬁnding that the p16INK4A promoter is demethylated and re-
expressed after 5-aza-CdR administration, we could also detect an
increased number of senescent cells upon 5-aza-CdR treatment.
Furthermore, in ALK þ ALCL the fusion protein NPM-ALK has been
implicated to be involved in epigenetic silencing of important
tumor suppressors such as SHP-1, STAT5A and IL-2Rg via its down-
stream target STAT3 [49e51]. Their re-expression leads to
suppression of NPM-ALK expression and, subsequently, induction
of apoptotic cell death. Therefore, it is tempting to speculate that
5-aza-CdR might exert part of its antineoplastic activity in ALKþ
ALCL via demethylation of these tumor suppressor genes.
In addition, Zhang et al. showed that the transcription factor
STAT3 can induce the expression of DNMT1 via miR-21, and vice
versa inhibition of DNMT1 leads to suppression of STAT3 activation
[24,51]. Considering that activated STAT3 is a key mediator of ALK
induced downstream signaling events and is involved in the
epigenetic silencing of tumor suppressors, inhibition of DNMT1 by
5-aza-CdR could have implications on the signaling pathways
affected by STAT3. Our pathway analysis of the global gene
expression data after 5-aza-CdR treatment listed STAT3 under the
top transcriptional regulators, indicating that several STAT3 regu-
lated proteins were affected by 5-aza-CdR. No relevant canonical
pathway in STAT3 or ALKþ mediated signaling was detected to be
de-regulated after inhibitor treatment, but possible changes in
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ALKþ targets, such as STAT3, are posttranscriptionally activated via
phosphorylation.
Currently, the efforts in therapeutic approaches of ALKþ and
other kinase driven malignancies concentrate on inhibition of the
kinase activity itself [52e54]. One prominent example is the tyro-
sine kinase inhibitor imatinib, which targets the bcr-abl oncopro-
tein in CML [55]. ALK speciﬁc inhibitors have been developed and
are intensively tested in preclinical settings with promising results
[56]. Despite good initial remission rates, targets of tyrosine kinase
inhibitors tend to accumulate mutations, which lead to therapy
resistance and tumor relapses of drug resistant cells [57,58]. We
propose that our in vitro and in vivo data with 5-aza-CdR on ALCL
suggest that an alternative option in these cases would be to target
de-regulated epigenetic mechanisms such as promoter hyper-
methylation in tumor cells, and apply 5-aza-CdR either as single
therapy or in combination with already established drugs.
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